Omeros (OMER) Long-Term Investments (2015 - 2018)
Omeros (OMER) posted Long-Term Investments of $1.2 million for Q4 2018, down 80.22% sequentially from $5.8 million in Q4 2017, and down 80.22% YoY from $5.8 million in Q4 2017.
Analysis
Omeros (OMER) Long-Term Investments (2015 - 2018) Analysis & Trends
Omeros has reported Long-Term Investments for 4 years, with the latest figure at $1.2 million in Q4 2018.
- Quarterly Long-Term Investments fell 80.22% year-over-year to $1.2 million in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $1.2 million (down 80.22% YoY) and the FY2018 annual result came in at $1.2 million, down 80.22% from the prior year.
- Long-Term Investments eased to $1.2 million in Q4 2018 per OMER's latest filing, from $5.8 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $10.7 million in Q4 2015 and troughed at $1.2 million in Q4 2018.
- A 4-year average of $5.9 million and a median of $5.8 million in 2016 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2017 and 2018: Long-Term Investments changed 0.0% in 2017, then slumped 80.22% in 2018.
- Over 4 years, Long-Term Investments stood at $10.7 million in 2015, then slumped by 45.36% to $5.8 million in 2016, then changed by 0.0% to $5.8 million in 2017, then sank by 80.22% to $1.2 million in 2018.
- According to Business Quant data, Long-Term Investments over the past three periods registered $1.2 million, $5.8 million, and $5.8 million for Q4 2018, Q4 2017, and Q4 2016 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Omeros | 1.38 Bn | 1.38 Bn | 27.73 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 1.15 Mn |
| Dec 31, 2017 | 5.84 Mn |
| Dec 31, 2016 | 5.84 Mn |
| Dec 31, 2015 | 10.68 Mn |